Selvita – integrated drug discovery partner

News Archive

Selvita appoints Dr Nicolas D. Beuzen as Chief Scientific Officer and Member of the Management Board

Selvita Sp. z o.o. , a drug discovery company headquartered in Krakow, Poland, announced today the appointment of Dr. Nicolas D. Beuzen as its Chief Scientific Officer and Member of the Management Board. Dr. Beuzen will oversee all Selvita’s drug research projects.

"Nicolas is a remarkable addition to our management team," stated Pawel Przewiezlikowski, Chief Executive Officer of Selvita. "His scientific and business education, as well as his experience with a big pharmaceutical company, a start-up and in outsourced drug development will provide an invaluable perspective for our future growth”.

Selvita Releases New Molecular Modeling Software for Life Science Researchers

Selvita releases its breakthrough protein structure prediction and protein-protein docking package for life science researchers with Selvita Protein Modeling Platform 2.0

Krakow, October 5, 2009 -- Selvita, a privately-held provider of products and services for biotechnology industry, today announced the release of Selvita Protein Modeling Platform 2.0 (SPMP 2.0), the latest version of its flagship protein discovery research software. This release features a new protein-protein docking module, usability enhancements, and improves discovery results for its users. SPMP 2.0 provides the necessary set of tools for protein structure and interactions modeling in web-based interface adapted for both beginner and expert users’ needs.

Dr. Nicolas Beuzen, Selvita’s Chief Scientific Officer, announced the new version release, saying: “For this major update of Selvita Protein Modeling Platform, our team of experts has been working at adding an unparalleled protein-protein docking module to the unique feature set of SPMP. This most important customer-requested enhancement completes our software offer in protein structure modeling. The core feature of the docking approach is to introduce a substantial degree of protein backbone flexibility during docking. Our technology allows users to predict protein-protein interactions on an unprecedented scale, surpassing previously available solutions in comparative benchmark studies. We have also improved our loop modeling and molecular mechanics optimization protocols together with 3D visualization functionalities and web-interface usability. Starting with homology modeling, broad range of tools, and together with unique structure prediction from sequence only and protein docking capabilities, SPMP 2.0 allows researchers to obtain comparative views of the protein structure and interactions data that they want to understand”.

“Protein structure predictive modeling is already advancing drug design by providing invaluable information on structure of protein-protein complexes” added Dr. Beuzen. “Antibodies are among the most promising drugs of the future. Selvita Protein Modeling Platform 2.0 will help scientists design and analyze new antibody-based drugs candidates with unmatched precision"

The key concept behind the Modeling Platform is the integration of state-of-the-art bioinformatics tools in a user-friendly web application, thus ensuring portability and interoperability among systems. Selvita Protein Modeling Platform 2.0 contains a robust core of unique structure prediction tools with high scientific credibility gained by its core algorithms in academic environment. Additional SPMP 2.0 components allow enhanced visualization capability, comparison of molecular models, sequence and structural analysis tailored to accelerate and simplify the discovery process.

The key modules of SPMP are:

- homology modeling , providing a complete procedure for structure prediction based on homologous structures, starting from sequence only;

- protein-protein docking, catering for a complete docking module including rigid-body docking, optional structural filtering according to user-provided data on interface residues and fully flexible docking approach;

- loop modeling , including loop structure prediction module from sequence only;

- de novo modeling for structure prediction module from sequence only.

For more information about the Selvita Protein Modeling Platform 2.0 please visit http://www.selvita.com/selvita-protein-modeling-platform.html
or contact Selvita at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

About Selvita:
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at lowering the cost of introducing innovative compounds to the market. The areas of our activity include: advanced protein modeling services and software; computer aided drug design; optimization of lead compounds; contract synthesis; information technology for research projects.
Selvita also develops its own research projects on innovative drugs up to the pre-clinical stage.

Contact:

Natalia Pawela
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
+48 12 6645305

Read-Gene and Selvita launch a strategic partnership in the area of genetic background of cancer development and its treatments

Read-Gene headquartered in Szczecin, Poland and Selvita, headquartered in Krakow, Poland announced today a strategic research, development and marketing partnership in the area of genetic background of neoplasm development and related treatments. The goal of the cooperation is to take advantage of the best of scientific, technical and business competencies of both companies in order to develop novel oncology diagnostics and treatment solutions. The foundation of the partnership is laid on twenty years of research of Read-Gene team into the genetic background of neoplasm development and its latest research on genomic-based targeting of cancer therapies. Selvita will contribute to the partnership scientific resources, bioinformatics tools and its expertise in the pharmaceutical market.